Panacea Biotec Limited (PANACEABIO)
ISIN: - Industry: Biotechnology Sector: Healthcare Website
155.9
-10.2(-6.14%)

Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

Pricing Updates

TODAY'S HIGH

172.45

TODAY'S LOW

152

52 WEEK HIGH

449

52 WEEK LOW

135

Major Holders

% of Shares Held by
All Insider

81.71%

% of Shares Held by
Institutions

0.00%

% of Float Held by
Institutions

0.00%

Number of Institutions
Holding Shares

0

Company Overview

MARKET CAP

956.12 Cr.

ETERPRISE VALUE

393.19 Cr.

NO. OF SHARES

6.12 Cr.

BOOK VALUE

-55.291

DIV. YIELD

0.75%

DEBT

34.15 Cr.

GROSS PROFIT

420.17 Cr.

CASH

588.28 Cr.

REVENUE

688.76 Cr.

REVENUE/SHARE

112.449

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2021Mar 2020Mar 2019Mar 2018
Investments-33.60 Cr.-45.22 Cr.-1.74 Cr.9.30 Lakhs
Change To Liabilities23.50 Cr.-49.68 Cr.7.50 Cr.31.27 Cr.
Total cashflows from Investing Activities-47.67 Cr.-34.76 Cr.-5.27 Cr.55.29 Cr.
Net Borrowings52.28 Cr.103.79 Cr.-34.75 Cr.-54.85 Cr.
Total Cash from Financing Activities-47.11 Cr.90.73 Cr.-101.14 Cr.-164.34 Cr.
Other Liabilities41.70 Cr.-1.65 Cr.31.70 Lakhs4.54 Cr.
Total Assets032 Cr.32 Cr.32 Cr.
Net Income-147.69 Cr.-194.26 Cr.37.72 Cr.-73.97 Cr.
Change in Cash11.86 Cr.25.75 Cr.-1.97 Cr.8.96 Cr.
Effect of Exchange Rate0000
Total Cash from Operating Activities106.65 Cr.-30.22 Cr.104.43 Cr.118.02 Cr.
Depreciation45.59 Cr.43.21 Cr.54 Cr.57.28 Cr.
Other Cashflows from Investing Activities3.43 Cr.5.26 Cr.1.25 Cr.-2.01 Cr.
Dividends Paid0000
Change to Inventory-26.44 Cr.-66.26 Cr.84.76 Cr.-18.83 Cr.
Change to Account Receivables-16.85 Cr.20.11 Cr.34.73 Cr.4.46 Cr.
Other Cashflows from Financing Activities-99.39 Cr.-45.05 Cr.-66.39 Cr.-109.49 Cr.
Change to Net Income186.84 Cr.218.31 Cr.-114.61 Cr.113.27 Cr.
Capital Expenditures-21.76 Cr.-6.91 Cr.-4.78 Cr.-15.21 Cr.

Financials

ParticularsMar 2021Mar 2020Mar 2019Mar 2018
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax-144.24 Cr.-171.22 Cr.48.61 Cr.-63.73 Cr.
Minority Interest-3 Cr.-3.03 Cr.-3 Cr.-2.94 Cr.
Net Income42.73 Cr.42.92 Cr.-110.55 Cr.41.53 Cr.
Selling General Administrative177.41 Cr.164.92 Cr.162.01 Cr.171.15 Cr.
Gross Profit420.17 Cr.387.26 Cr.284.45 Cr.405.54 Cr.
Ebit42.73 Cr.42.92 Cr.-110.55 Cr.41.53 Cr.
Operating Income42.73 Cr.42.92 Cr.-110.55 Cr.41.53 Cr.
Other Operating Expenses154.43 Cr.136.19 Cr.178.98 Cr.135.57 Cr.
Interest Expense-184.69 Cr.-173.11 Cr.-84.96 Cr.-96.35 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense1.95 Cr.16.64 Cr.7.70 Cr.9.85 Cr.
Total Revenue624.80 Cr.544.06 Cr.456.69 Cr.592.79 Cr.
Total Operating Expenses582.07 Cr.501.13 Cr.567.24 Cr.551.26 Cr.
Cost of Revenue204.63 Cr.156.79 Cr.172.24 Cr.187.24 Cr.
Total Other Income Expense Net-186.97 Cr.-214.14 Cr.159.16 Cr.-105.26 Cr.
Discontinued Operations-1.45 Cr.-6.43 Cr.-3.24 Cr.-2.40 Cr.
Net Income from Continuous Ops.-146.20 Cr.-187.86 Cr.40.90 Cr.-73.59 Cr.
Net Income Applicable to Common Shares-147.69 Cr.-194.26 Cr.37.72 Cr.-73.97 Cr.

Balance Sheet

ParticularsMar 2021Mar 2020Mar 2019Mar 2018
Intangible Assets13.97 Cr.15.44 Cr.15.19 Cr.34.84 Cr.
Capital Surplus91.94 Cr.91.94 Cr.91.94 Cr.91.94 Cr.
Total Liabilities1410.50 Cr.1194.55 Cr.1028.13 Cr.1301.83 Cr.
Stock Holder Equity-250.34 Cr.176.99 Cr.340.75 Cr.299.03 Cr.
Minority Interest-3 Cr.-3.03 Cr.-3 Cr.-2.94 Cr.
Other Liabilities77.97 Cr.66.60 Cr.56.73 Cr.22.86 Cr.
Total Assets1178.81 Cr.1390.30 Cr.1375.52 Cr.1607.55 Cr.
Common Stock6.12 Cr.6.12 Cr.6.12 Cr.6.12 Cr.
Retained Earnings-174.50 Cr.-60.21 Cr.135.91 Cr.98.83 Cr.
Other Liabilities249.76 Cr.129.47 Cr.43.74 Cr.40.08 Cr.
Good Will00089.60 Lakhs
Treasury Stock-173.90 Cr.139.13 Cr.106.77 Cr.102.13 Cr.
Other Assets25.42 Cr.20.97 Cr.35.61 Cr.55.82 Cr.
Cash52.07 Cr.40.21 Cr.14.46 Cr.16.43 Cr.
Current Liabilities425.66 Cr.451.94 Cr.938.26 Cr.691.03 Cr.
Long Term Asset Charges14.70 Lakhs1.94 Cr.19.79 Cr.19.66 Cr.
Short Long Term Debt84.44 Cr.125.49 Cr.530.98 Cr.205.15 Cr.
Other Stockholder Equity-173.90 Cr.139.13 Cr.106.77 Cr.102.13 Cr.
Property Plant Equipment627.89 Cr.665.03 Cr.811.50 Cr.950.39 Cr.
Total Cur. Assets510.97 Cr.683.27 Cr.507.88 Cr.560.34 Cr.
Long Term Investments55.20 Lakhs5.58 Cr.5.32 Cr.5.24 Cr.
Net Tangible Assets-264.31 Cr.161.54 Cr.325.56 Cr.263.29 Cr.
Short Term Investments4.26 Cr.3.09 Cr.00
Net Receivables95.32 Cr.76.05 Cr.109.60 Cr.175.71 Cr.
Long Term Debt735.08 Cr.613.12 Cr.46.12 Cr.570.70 Cr.
Inventory174.13 Cr.147.69 Cr.81.42 Cr.334.20 Cr.
Accounts Payable221.94 Cr.198.85 Cr.269.71 Cr.277.19 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account